- Home
- CTO vs KROS Comparison
CTO vs KROS Comparison
Compare CTO & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTO
- KROS
- Stock Information
- Founded
- CTO 1902
- KROS 2015
- Country
- CTO United States
- KROS United States
- Employees
- CTO N/A
- KROS N/A
- Industry
- CTO Real Estate Investment Trusts
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- CTO Real Estate
- KROS Health Care
- Exchange
- CTO Nasdaq
- KROS Nasdaq
- Market Cap
- CTO 589.6M
- KROS 558.9M
- IPO Year
- CTO N/A
- KROS 2020
- Fundamental
- Price
- CTO $17.90
- KROS $13.45
- Analyst Decision
- CTO Strong Buy
- KROS Buy
- Analyst Count
- CTO 3
- KROS 13
- Target Price
- CTO $22.33
- KROS $20.63
- AVG Volume (30 Days)
- CTO 374.3K
- KROS 603.2K
- Earning Date
- CTO 07-29-2025
- KROS 08-06-2025
- Dividend Yield
- CTO 8.59%
- KROS N/A
- EPS Growth
- CTO N/A
- KROS N/A
- EPS
- CTO N/A
- KROS 0.11
- Revenue
- CTO $132,203,000.00
- KROS $214,713,000.00
- Revenue This Year
- CTO $20.11
- KROS $5,006.76
- Revenue Next Year
- CTO $8.51
- KROS N/A
- P/E Ratio
- CTO N/A
- KROS $123.44
- Revenue Growth
- CTO 17.48
- KROS 91657.70
- 52 Week Low
- CTO $16.12
- KROS $9.12
- 52 Week High
- CTO $21.15
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- CTO 43.15
- KROS 45.45
- Support Level
- CTO $17.10
- KROS $13.24
- Resistance Level
- CTO $17.71
- KROS $13.77
- Average True Range (ATR)
- CTO 0.36
- KROS 0.37
- MACD
- CTO -0.06
- KROS -0.04
- Stochastic Oscillator
- CTO 47.50
- KROS 38.67
About CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties comprised of approximately 2.7 million square feet in diversified markets in the United States. Its portfolio of assets consists of Income Properties Portfolio, management services, Commercial Loan and Investments.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.